Business Context and Reporting Period
This Form 8-K is a current report filed by Mind Medicine (MindMed) Inc. on June 16, 2023. The filing addresses the outcome of the Company's 2023 Annual General Meeting of Shareholders held on June 15, 2023, and the subsequent reconvening of the meeting.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's Form 10-K for the year ended December 31, 2022, or Form 10-Q for the quarter ended March 31, 2023, for financial performance details.
Material Changes and Events
- Failed Quorum: The Annual General Meeting convened on June 15, 2023, was adjourned without conducting business because the required quorum of 33 1/3% of outstanding common shares was not achieved.
- Reconvened Meeting: The meeting has been rescheduled for June 21, 2023, at 10:00 a.m. Eastern Time. It will be held virtually.
- Quorum Rules: Under the Company's Articles, if the 33 1/3% quorum is not present within 30 minutes of the reconvened meeting start time, the persons present will constitute a quorum, even if less than the stated percentage.
- Solicitation Efforts: The Company reported significant efforts to secure a quorum, including retaining proxy solicitor Morrow Sodali LLC, mailing proxy statements to over 220,000 beneficial owners, and issuing over 15 press releases.
Outlook, Risks, and Contingencies
- Nasdaq Listing Risk: There is a risk that Nasdaq may determine the Company's Articles (specifically the provision allowing a quorum of persons present if the stated quorum is not met) are inconsistent with Nasdaq Listing Rule 5620(c).
- Compliance Timeline: If Nasdaq issues a non-compliance letter, the Company would have 45 days to submit a compliance plan and potentially up to 180 days to evidence compliance.
- Delisting Consequences: If the Company is ultimately delisted, it could adversely affect the liquidity, volatility, and market price of its common shares, reduce investor interest, and negatively impact the ability to access equity markets for financing.
- Forward-Looking Statements: The Company cautions that there is no assurance it will be able to regain compliance with Nasdaq rules or that the reconvened meeting will achieve a quorum.
Investor Verification Checklist
- Verify the outcome of the reconvened Annual Meeting on June 21, 2023, and whether a quorum was achieved.
- Monitor communications from Nasdaq regarding the Company's compliance with Rule 5620(c) and the validity of its Articles.
- Review the definitive proxy statement (Schedule 14A) filed on May 1, 2023, for details on board nominees and shareholder proposals.
- Assess the potential impact of a Nasdaq delisting on the Company's ability to raise capital and the trading liquidity of MNMD shares.